Home › Migraine › Illinois › Chicago
Migraine clinical trials in Chicago, IL
4 studies for Migraine are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
RecruitingPhase 3
- Cedar Crosse Research Center, Chicago
- Chicago Headache Center & Research Institute, Chicago
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
RecruitingPhase 3
- Chicago Headache Center & Research Institute, Chicago
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
RecruitingPhase 3
- Chicago Headache Center & Research Institute, Chicago
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RecruitingPhase 3
- Chicago Headache Center & Research Institute /ID# 248625, Chicago
About Migraine
Migraines are pulsing or throbbing headaches in one area of the head. Learn about other symptoms, what triggers migraines, and how to treat them.
More about Migraine on MedlinePlus
Migraine trials in other cities
- Cincinnati, OH12 studies
- Omaha, NE9 studies
- Austin, TX9 studies
- Aurora, CO8 studies
- Miami, FL8 studies
- Stamford, CT8 studies
- Atlanta, GA8 studies
- Washington, DC8 studies
- Phoenix, AZ7 studies
- Philadelphia, PA7 studies
- Tampa, FL7 studies
- San Diego, CA7 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.